300110.SZ Stock Analysis
30
Neutral
Based on Eyestock quantitative analysis, 300110.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Huaren Pharmaceutical Co., Ltd. engages in development, manufacture, and sale of non polyvinyl chloride and non-PVC large capacity preparations. The company is headquartered in Qingdao, Shandong and currently employs 2,242 full-time employees. The company went IPO on 2010-08-25. The firm provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The firm distributes its products in domestic market, with Northeast China as its main market.